Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

BACKGROUND: Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA). OBJECTIVE: To evaluate differences in response up to week 52 among subgroups based on the baseline severity of AA assessed with the Severity of Alopecia Tool (SAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Susan, Korman, Neil J., Tsai, Tsen-Fang, Shimomura, Yutaka, Feely, Meghan, Dutronc, Yves, Wu, Wen-Shuo, Somani, Najwa, Tosti, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689675/
https://www.ncbi.nlm.nih.gov/pubmed/37740856
http://dx.doi.org/10.1007/s13555-023-01033-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689675/
https://www.ncbi.nlm.nih.gov/pubmed/37740856
http://dx.doi.org/10.1007/s13555-023-01033-8

Ejemplares similares